Nebula Genomics leverages blockchain technology to eliminate middlemen and empower people to own their personal genomic data.
Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 10, 2018 | Series A | $4.30M | 12 | Khosla Ventures | — | Detail |
Jan 1, 2018 | Seed | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Khosla Ventures | Yes | Series A |
ARCH Venture Partners | — | Series A |
F-Prime Capital | — | Series A |
Fenbushi Capital | — | Series A |
Great Point Partners | — | Series A |
Heartbeat Labs | — | Series A |
Hemi Ventures | — | Series A |
Hikma Ventures | — | Series A |
Mayfield Fund | — | Series A |
Mirae Asset | — | Series A |